Disclosed are a near-infrared absorbing composition, an optical structure, and a camera module and an electronic device including the same. The near-infrared absorbing composition includes a copper complex represented by Chemical Formula 1. ##STR00001##
Definitions of Chemical Formula 1 are the same as described in the detailed description.

One-step methods for forming phosphate-based enzyme inhibitors are disclosed. Methods include reacting o-phosphorylethanolamine with an acyl chloride at acidic conditions. Acyl chlorides can be derivatized. The phosphate-based enzyme inhibitors can inhibit enzymes of the pentose phosphate pathway including D-ribose-5-phosphate aldose-ketose isomerase enzymes such as T. cruzi ribose 5-phosphate isomerase type B and D-ribulose-5-phosphate 3-epimerase enzymes. Methods can be used in forming pharmaceutical compositions for use in treatment of disease caused by kinetoplastid parasites including T. cruzi, T. brucei, and Leishmania spp.

One-step methods for forming phosphate-based enzyme inhibitors are disclosed. Methods include reacting o-phosphorylethanolamine with an acyl chloride at acidic conditions. Acyl chlorides can be derivatized. The phosphate-based enzyme inhibitors can inhibit enzymes of the pentose phosphate pathway including D-ribose-5-phosphate aldose-ketose isomerase enzymes such as T. cruzi ribose 5-phosphate isomerase type B and D-ribulose-5-phosphate 3-epimerase enzymes. Methods can be used in forming pharmaceutical compositions for use in treatment of disease caused by kinetoplastid parasites including T. cruzi, T. brucei, and Leishmania spp.

The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Provided is a medical suture thread which is less likely to remain curled or is easily uncurled from a curled state. The medical suture thread 100 includes a core thread 110 and an outer thread 120. The core thread 110 includes multiple twisted ultrafine threads 111, and is arranged at a center portion of the medical suture thread 100. In the ultrafine thread 111, an inner-filament cover layer 112 made of 2-methacryloyloxyethyl phosphorylcholine (MPC) is formed on an outer surface of a filament 111a. The outer thread 120 is formed to be braided with multiple ultrafine threads 121, and covers an outer surface of the core thread 110. In the ultrafine thread 121, an outer-filament cover layer 122 made of MPC is formed on an outer surface of a filament 121a. The inner-filament cover layer 112 and the outer-filament cover layer 122 are respectively formed on the outer surfaces of the filaments 111a, 121a within a weight range of equal to or greater than 0.05% and less than 0.3% with respect to the total weight of each of the filaments 111a, 121a, respectively.

A nonaqueous electrolyte secondary battery according to one embodiment of the present disclosure comprises a positive electrode, a negative electrode and a nonaqueous electrolyte solution; the negative electrode comprises a negative electrode collector and a negative electrode active material layer that is provided on the negative electrode collector; the negative electrode active material layer contains, as negative electrode active materials, graphite particles A and graphite particles B; the graphite particles A have an internal void fraction of 5% or less; the graphite particles B have an internal void fraction of from 8% to 20%; if the negative electrode active material layer is halved in the thickness direction, a region on the half closer to the outer surface contains more graphite particles A than a region on the half closer to the negative electrode collector.

A nonaqueous electrolyte secondary battery according to one embodiment of the present disclosure comprises a positive electrode, a negative electrode and a nonaqueous electrolyte solution; the negative electrode comprises a negative electrode collector and a negative electrode active material layer that is provided on the negative electrode collector; the negative electrode active material layer contains, as negative electrode active materials, graphite particles A and graphite particles B; the graphite particles A have an internal void fraction of 5% or less; the graphite particles B have an internal void fraction of from 8% to 20%; if the negative electrode active material layer is halved in the thickness direction, a region on the half closer to the outer surface contains more graphite particles A than a region on the half closer to the negative electrode collector.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.